A TRIO study by Diez‐Perez et al. showed that PINP and CTX were measured at baseline and at 3 months after oral bisphosphonate therapy, and follow‐up treatment management was determined by examining the least significant change (reduction of PINP and CTX by more than 38% and 56%, respectively), suggesting that BTM had a profound effect on the observation of osteoporosis therapy14. This evidence concerns the gene CYP27A1 and osteoporosis.